Journal of Allergy and Clinical Immunology
Drug hypersensitivity: Pharmacogenetics and clinical syndromes
Section snippets
Pharmacogenetics of drug hypersensitivity
Associations between HLA alleles and specific drug hypersensitivity syndromes, such as abacavir hypersensitivity, have been paradigm shifting in heralding the widespread use of a pharmacogenetic test in clinical practice to prevent the development of a specific life-threatening drug toxicity. More recently, HLA associations between DRESS/DIHS and SJS/TEN have been described (Table I).1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 Identifying the true phenotypic drug
References (47)
- et al.
Association between presence of HLA-B∗5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir
Lancet
(2002) - et al.
Genetic variations in HLA-B region and hypersensitivity reactions to abacavir
Lancet
(2002) Clinical heterogeneity of drug hypersensitivity
Toxicology
(2005)- et al.
Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel
J Am Acad Dermatol
(2008) - et al.
HLA-B∗5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol
Proc Natl Acad Sci U S A
(2005) - et al.
HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis
Pharmacogenomics
(2008) - et al.
Strong association between HLA-B∗5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population
Pharmacogenet Genomics
(2009) - et al.
A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs
Pharmacogenet Genomics
(2008) - et al.
Medical genetics: a marker for Stevens-Johnson syndrome
Nature
(2004) - et al.
Association between HLA-B∗1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese
Epilepsia
(2007)
Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B∗1502 allele in Thai population
Epilepsia
Association of HLA-B∗1502 allele and carbamazepine-induced Stevens-Johnson syndrome among Indians
Indian J Dermatol Venereol Leprol
HLA Class I markers in Japanese patients with carbamazepine-induced cutaneous adverse reactions
Epilepsia
Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese
Pharmacogenomics
HLA-B∗5701 screening for hypersensitivity to abacavir
N Engl J Med
High sensitivity of human leukocyte antigen-B∗5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients
Clin Infect Dis
Predisposition to nevirapine hypersensitivity associated with HLA-DRB1∗0101 and abrogated by low CD4 T-cell counts
AIDS
HLA-dependent hypersensitivity to nevirapine in Sardinian HIV patients
AIDS
HLA-Cw8 primarily associated with hypersensitivity to nevirapine
AIDS
HLA-B∗ 3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients
Pharmacogenet Genomics
HLA-B∗35 is associated with nevirapine hypersensitivity in the contemporary Western Australian HIV cohort study
Eur Ann Allergy Clin Immunol
Utility of patch testing in patients with hypersensitivity syndromes associated with abacavir
AIDS
Cited by (0)
Publication of this article was supported by iDea Congress. The RegiSCAR-study was funded by grants from the European Commission (QLRT-2002-01738), GIS-Institut des Maladies Rares and INSERM (4CH09G) in France, and by a consortium of pharmaceutical companies (Bayer Vital, Boehringer-Ingelheim, Cephalon, GlaxoSmithKline, MSD Sharp and Dohme, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis, Servier). M.M. received the Else Kröner Memorial Stipendium for support of clinical research through Else Kröner-Fresenius-Foundation, Germany. The GWAS was performed in collaboration with Centre National de Genotypage (CNG), France.
Disclosure of potential conflict of interest: E. J. Phillips has received honoraria from Merck, ViiV Healthcare, and Tibotec Johnson & Johnson and has received research support from the National Health and Medical Research Council, Australia. W.-H. Chung has received research support from the National Science Council Taiwan and Chang Gung Memorial Hospital. M. Mockenhaupt has received research support from CNG and EC. J.-C. Roujeau has received research support from GlaxoSmithKline, Boehringer Ingelheim France, Novartis Pharma, Astellas Pharma SAS, Science et Technologie, and OM Pharma. S. A. Mallal has received honoraria from ViiV Healthcare, MSD, and Tibotec Johnson & Johnson and has received research support from the National Health and Medical Research Council and the National Institutes of Health.